RarePlex HER2/ER CTC Panel Kit
Panel Kit for Breast Cancer Markers
Panel Kits – Enumeration | ARv7| AR/ARv7 | SYP | ARv7/SYP | HER2/ER | PD-L1
Developer Kits – 405/488
Download Specification Sheets
Download Test Menu Catalog
The RarePlex ARv7 CTC Panel Kit (0913-LB) enables detection of androgen receptor splice variant 7 (ARv7) expression by circulating tumor cells. Androgen-mediated signaling is the predominant driver of prostate cancer proliferation. ARv7 is a constitutively active AR splice variant and is a difficult to detect diagnostic prostate cancer biomarker that is associated with resistance to second generation therapies.
As prostate cancer is a rapidly evolving field where studies identifying and characterizing new biomarkers aim to identify a cancer-halting treatment, assay flexibility is required to keep pace with circulating tumor cell discoveries. The ARv7 Panel Kit is designed to allow you to add an additional biomarker of your choice with a Developer Kit.
What is Included in this Prostate Cancer Panel Kit for Tumor Markers?
The ARv7 Panel Kit includes all reagents needed to detect ARv7, CK/EpCAM, CD45, and nuclei on AccuCyte slides. Extensive kit validation demonstrated high accuracy, repeatability, and inter-run precision, making the ARv7 Panel Kit ideal for use in large, multi-center clinical trials.
RareCyte’s deployable platform for circulating tumor cell analysis in cancer research:
- A clinical research laboratory can process blood to slides to result in their own lab
- Platform produces accurate and highly reproducible results
Convenient pause points in workflow enable shipping between sites - Flexibility in sample processing – A site can process AccuCyte slides and/or perform staining and analysis
- Leverage worldwide network of contract research organizations
BT474 stained with the 0901-VB HER2/ER CTC Panel Kit.
Scale bar represents 10μm.
BT474 stained with the 0901-VB HER2/ER CTC Panel Kit.
Scale bar represents 10μm.
Additional resources for the RarePlex ARv7 Panel Kit
Download the specification sheet →
What are the most common Breast Cancer Tumor Markers for Diagnosis and Research?
Breast Cancer research uses tumor markers, or serum markers produced by tumor cells, to identify the presence of breast cancer. Although most of these biomarkers can also be made by the normal cells, they are produced at much higher levels in cancerous conditions. Breast cancer markers can be used to evaluate the patient’s response to treatment or to detect the presence of metastasis or recurrence. The CA 27-29, CA 15-3, CA27.29, carcinoembryonic antigen, tissue polypeptide specific antigen, p53, cathepsin D, cyclin E, nestin and HER-2 are tumor markers that are often expressed in people with breast cancer. Three of these tumor markers — cancer antigen 15-3 (CA 15-3), cancer antigen 27.29 (CA 27.29), and carcinoembryonic antigen (CEA) — have been used to help monitor metastatic breast cancer specifically.
Clinical breast cancer samples stained with the HER2/ER CTC Panel Kit.
Scale bar represents 10μm.
Clinical breast cancer samples were analyzed with the RarePlex HER2/ER CTC Panel Kit, a CyteFinder Instrument, and CyteMapper software. Results from a single clinical sample are shown. Mean fluorescence intensity thresholds for positivity are shown in the dashed copper lines and were defined by known model circulating tumor cells.
RarePlex® Assays: Design and Analytical Validation for Tumor Marker Testing
Presented by Dr. Tad George, Sr. VP of Biology R&D. RarePlex Assays are sensitive, specific, and reproducible assays for CTC detection and biomarker expression. Gain insight into the principles RareCyte applies to its assay design and validation process in this 11 minute video.